A newborn with petechiae.

Tidsskr Nor Laegeforen

Department for Children and Adolescents, Ålesund Hospital, Norway.

Published: April 2013

Download full-text PDF

Source
http://dx.doi.org/10.4045/tidsskr.12.1009DOI Listing

Publication Analysis

Top Keywords

newborn petechiae
4
newborn
1

Similar Publications

Fetal and neonatal alloimmune thrombocytopenia (FNAIT) results from maternal antibodies targeting fetal platelets during pregnancy, often causing hemorrhagic manifestations detectable antenatally or shortly after birth. We report an atypical form of FNAIT with delayed onset in a healthy, breastfed male infant who developed diffuse petechiae 2 weeks after birth due to severe thrombocytopenia. The mother was shown to be negative for the human platelet antigen-1a (HPA-1a) allele but had anti-HPA-1a IgG antibodies, while the father and newborn were HPA-1a positive, confirming the diagnosis.

View Article and Find Full Text PDF

Efficacy and tolerability of celastrol and edaravone in the multiple-hit rat model of infantile spasms.

Epilepsy Behav

January 2025

Albert Einstein College of Medicine, Saul R. Korey Department of Neurology, Laboratory of Developmental Epilepsy, Albert Bronx, NY, USA; Isabelle Rapin Division of Child Neurology, Albert Einstein College of Medicine, Bronx, NY, USA; Dominick P Purpura Department of Neuroscience, Albert Einstein College of Medicine, Bronx, NY, USA. Electronic address:

Objective: To test whether anti-inflammatory and antioxidant drugs that inhibit the nuclear factor kappa light chain enhancer of activated B cells (NF-kB), celastrol and edaravone, suppress spasms and improve developmental outcomes in the multiple-hit rat model of refractory infantile spasms (IS) due to structural lesions.

Methods: Postnatal day 3 (PN3) Sprague-Dawley rats were treated according to the multiple-hit IS model protocol. Using a randomized, blinded, vehicle-controlled, dose- and time-response study design, we tested the effects of single celastrol [1, 2, or 4 mg/kg intraperitoneally (i.

View Article and Find Full Text PDF
Article Synopsis
  • PC is a crucial plasma anticoagulant, and mutations in both alleles can lead to a serious condition called neonatal purpura fulminans.
  • The study developed a genome editing approach using engineered activated protein C (APC) to treat congenital PC deficiency by expressing it in mouse liver through adeno-associated virus vectors and CRISPR/Cas9.
  • Results showed that the engineered APC prolonged coagulation time, inhibited harmful thrombus formation, and improved the survival of PC-deficient mice, indicating its potential as a cure for this severe condition.
View Article and Find Full Text PDF

Congenital protein C (PC) deficiency is a mostly autosomal dominant hereditary thrombophilia associated with early onset arterial and venous thrombotic diseases. In newborns, PC deficiency results in severe complications such as cerebral hemorrhage, cerebral infarction, and purpura fulminans, leading to death in some cases. We report two cases of deep vein thrombosis diagnosed during pregnancy that prompted genetic testing confirming definitive congenital PC deficiency.

View Article and Find Full Text PDF

Immune thrombocytopenic purpura (ITP) affects 1-3 out of every 10 000 pregnancies, posing significant risks to both mothers and newborns. The condition often requires careful management to prevent severe hemorrhagic events. PubMed, Embase, Scopus, and Web of Science searched for relevant literature until June 2024.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!